EUVIMEDEUVIMED entdecken
Crossref

2864-LB: TRPM4 Protein Is Required for Semaglutide (Ozempic)-Stimulated Insulin Secretion in Pancreatic Beta Cells

HENRIQUE CHENG

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2864-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von HENRIQUE CHENG.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Semaglutide, marketed as Ozempic®, is a medication prescribed for diabetes management, known for its dual action of enhancing insulin secretion and reducing appetite. Despite its recognized clinical benefits, the exact cellular mechanisms regulating semaglutide-induced insulin secretion are not fully understood. This study aimed to explore the regulatory role of TRPM4 in semaglutide-mediated insulin secretion.

Methods

Using real-time calcium imaging analysis and the ratiometric calcium indicator Fura-2AM, intracellular signals were measured in response to different concentrations of semaglutide and 9-Phenanthrol, a specific TRPM4 inhibitor. Additionally, insulin secretion experiments were conducted to measure the effects of semaglutide and 9-Phenanthrol on insulin release from β cells.

Results

The results revealed that semaglutide increased intracellular calcium in a concentration-dependent manner, and stimulated insulin secretion. Notably, inhibition of TRPM4 by 9-Phenanthrol abolished the responses to semaglutide during intracellular calcium measurements and insulin release experiments.

Conclusion

In conclusion, this study sheds light on the pivotal role of TRPM4 in controlling intracellular calcium dynamics and insulin secretion triggered by semaglutide in pancreatic β cells. Such findings contribute to a deeper understanding of the mechanisms underlying semaglutide therapy in diabetes management. Disclosure H. Cheng: None. Funding Ferguson College of Agriculture and College of Veterinary Medicine at Oklahoma State University, and Thai Royal Golden Jubilee Research Program, Thailand.

Zitieren

APA

CHENG, H. (2026). 2864-LB: TRPM4 Protein Is Required for Semaglutide (Ozempic)-Stimulated Insulin Secretion in Pancreatic Beta Cells. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2864-lb

Vancouver

CHENG H. 2864-LB: TRPM4 Protein Is Required for Semaglutide (Ozempic)-Stimulated Insulin Secretion in Pancreatic Beta Cells. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2864-lb

BibTeX
@article{CHENG2026,
  author = {CHENG, HENRIQUE},
  title = {2864-LB: TRPM4 Protein Is Required for Semaglutide (Ozempic)-Stimulated Insulin Secretion in Pancreatic Beta Cells},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2864-lb}
}
Kostenlos starten →